← Back to Search

Contingency Management for Opioid Use Disorder

N/A
Waitlist Available
Led By August Holtyn
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial will compare the effectiveness of two different contingency management interventions for treating adults with opioid use disorder.

Who is the study for?
This trial is for adults with opioid use disorder who are currently enrolled in buprenorphine treatment. Participants must be willing and able to use a smartphone, as the study involves remote verification of medication adherence and abstinence through video.Check my eligibility
What is being tested?
The study tests two Contingency Management strategies against Standard Medical Management. One group gets incentives for taking buprenorphine daily, another also gets rewards for opiate-free saliva samples, while the third receives usual care without these incentives.See study design
What are the potential side effects?
Since this trial focuses on behavioral interventions rather than medications, there are no direct side effects from drugs being tested. However, participants may experience stress or disappointment if they do not meet goals and miss out on incentives.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Buprenorphine adherence as assessed by the percentage of buprenorphine-positive urine samples
Opiate abstinence as assessed by the percentage of opiate-negative urine samples
Secondary outcome measures
Buprenorphine diversion as assessed by the rates at which participants report diverting participants' buprenorphine

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Buprenorphine Adherence and Opiate AbstinenceExperimental Treatment2 Interventions
Participants will receive financial incentives for buprenorphine use and opiate abstinence.
Group II: Buprenorphine Adherence OnlyExperimental Treatment1 Intervention
Participants will receive financial incentives for buprenorphine use.
Group III: ControlActive Control1 Intervention
Participants will not receive any intervention.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,285 Previous Clinical Trials
14,842,690 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
563 Previous Clinical Trials
29,991,775 Total Patients Enrolled
August HoltynPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
8 Total Patients Enrolled

Media Library

Contingency Management for adherence Clinical Trial Eligibility Overview. Trial Name: NCT04024059 — N/A
Opioid Use Disorder Research Study Groups: Buprenorphine Adherence Only, Control, Buprenorphine Adherence and Opiate Abstinence
Opioid Use Disorder Clinical Trial 2023: Contingency Management for adherence Highlights & Side Effects. Trial Name: NCT04024059 — N/A
Contingency Management for adherence 2023 Treatment Timeline for Medical Study. Trial Name: NCT04024059 — N/A
~69 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top